Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Leki | Leki |
| Evidence strength | Moderate evidence | Strong evidence |
| Evidence Score | 3/5 | 5/5 |
| User rating | 4.3 (58) | 4.5 (58) |
| Typical dose | In approved indications: usually 200 mg once daily in the morning (narcolepsy, sleep apnea) or about an hour before a night shift begins (shift-work disorder) — by prescription and under medical supervision only | Start at 2.5 mg weekly, gradual escalation every 4 weeks to a maintenance dose of 5, 7.5, 10, 12.5, or a maximum of 15 mg weekly, depending on tolerance and treatment goal |
| Form | Oral tablets | Solution for subcutaneous injection in a single-use autoinjector (Mounjaro, Zepbound) |
| Average price | Lek na receptę — cena i refundacja zależą od wskazania, zwykle 60–150 zł za opakowanie bez refundacji | ok. 1000–1600 zł za opakowanie miesięczne, zależnie od dawki i apteki |
| Monthly cost | ok. 60–150 zł/miesiąc przy codziennym stosowaniu bez refundacji | ok. 1000–1600 zł/miesiąc |
| Time to effects | The wake-promoting effect usually appears within 1–2 hours of taking a dose and lasts most of the day due to its long half-life (about 12–15 hours). | Reduced appetite is sometimes noticeable within the first few weeks, but meaningful, measurable weight loss develops gradually over several months, and the full effect assessed in SURMOUNT-1 was measured after 72 weeks (about 1.5 years) of regular treatment. |
| Who it's for | Patients with a confirmed narcolepsy diagnosis, qualified by a neurologist or sleep medicine specialist | People with type 2 diabetes with inadequate glycemic control on other oral medications |